Structure Therapeutics Inc. American Depositary Shares (GPCR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.43B
Last updated: Nov 17, 2026 at 11:06 AM ET
Structure Therapeutics Inc. American Depositary Shares (GPCR) Competitors
The companies most similar to Structure Therapeutics Inc. American Depositary Shares are Beam Therapeutics (BEAM), Theravance Biopharma (TBPH) and Mineralys Therapeutics, Inc. Common Stock (MLYS). By market cap, Structure Therapeutics Inc. American Depositary Shares ranks 6th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B.
Peer Comparison
GPCR's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | $1.36B | N/A | N/A | 0.0% | -51.1% | 0.0% | 0.00% |
| Ocular Therapeutix Inc (OCUL) | $1.37B | N/A | 26.9x | 0.0% | -52.1% | -11.5% | 0.00% |
| Tyra Biosciences Inc (TYRA) | $1.38B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Design Therapeutics Inc (DSGN) | $670.46M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Vera Therapeutics Inc (VERA) | $2.03B | N/A | 189.3x | 0.0% | -83.0% | 0.0% | 0.00% |
| Silence Therapeutics PLC (SLN) | $1.23B | N/A | 882.5x | 0.0% | N/A | 197.2% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Sarepta Therapeutics Inc (SRPT) | $1.72B | N/A | 0.8x | -5.9% | -3.2% | -4.5% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Trevi Therapeutics Inc (TRVI) | $1.95B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $1.37B | 95.1x | 20.9x | 0.0% | -51.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Structure Therapeutics Inc. American Depositary Shares, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular... | MLYS competitors |
| Ocular Therapeutix Inc (OCUL) | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development... | OCUL competitors |
| Tyra Biosciences Inc (TYRA) | Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes... | TYRA competitors |
| Design Therapeutics Inc (DSGN) | Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. | DSGN competitors |
| Vera Therapeutics Inc (VERA) | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases... | VERA competitors |
| Silence Therapeutics PLC (SLN) | Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology... | SLN competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Sarepta Therapeutics Inc (SRPT) | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy... | SRPT competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| Trevi Therapeutics Inc (TRVI) | Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious... | TRVI competitors |
Frequently Asked Questions About GPCR
Who are Structure Therapeutics Inc. American Depositary Shares' main competitors?
The companies most similar to Structure Therapeutics Inc. American Depositary Shares include Beam Therapeutics (BEAM), Theravance Biopharma (TBPH), Mineralys Therapeutics, Inc. Common Stock (MLYS), Ocular Therapeutix (OCUL) and Tyra Biosciences (TYRA), listed from the closest match.
Who is Structure Therapeutics Inc. American Depositary Shares' biggest competitor?
Beam Therapeutics (BEAM) is both the largest of the similar companies at $2.36B and the closest match by business profile, size, sector and industry.
How does GPCR stock compare with its competitors?
GPCR's net margin is 0.0% against a peer median of 0.0%.
Which of Structure Therapeutics Inc. American Depositary Shares' competitors pays a higher dividend?
Structure Therapeutics Inc. American Depositary Shares pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Structure Therapeutics Inc. American Depositary Shares bigger than its competitors?
No. Structure Therapeutics Inc. American Depositary Shares is 6th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.
GPCR pages: Overview, Earnings, Forecast, Financials, Competitors